Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate

Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 Pyrazole NNRTIs 1: Design and initial optimisation of a novel template 1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents Discovery of 3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency against Key Mutant Viruses Pyrazole NNRTIs 3: Optimisation of physicochemical properties Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase 4,1-Benzoxazepinone analogues of efavirenz (Sustiva™) as HIV-1 reverse transcriptase inhibitors Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1